Back to Search Start Over

Validation of recombinant Sendai virus in a non-natural host model

Authors :
Alison Baker
T Owaki
Eilidh Baker
Eric W.F.W. Alton
David Collie
Christina Vrettou
Mamoru Hasegawa
Catherine Gordon
L Somerton
Uta Griesenbach
Gerry McLachlan
Peter Tennant
T Shu
Source :
Gene Therapy. 18:182-188
Publication Year :
2010
Publisher :
Springer Science and Business Media LLC, 2010.

Abstract

We have previously shown that recombinant Sendai virus (SeV) vector, derived from murine parainfluenza virus, is one of the most efficient vectors for airway gene transfer. We have also shown that SeV-mediated transfection on second administration, although reduced by 60% when compared with levels achieved after a single dose, is still high because of the efficient transfection achieved by SeV vector in murine airways. Here, we show that these levels further decrease on subsequent doses. In addition, we validated SeV vector repeat administration in a non-natural host model, the sheep. As part of these studies we first assessed viral stability in a Pari LC Plus nebuliser, a polyethylene catheter (PEC) and the Trudell AeroProbe. We also compared the distribution of gene expression after PEC and Trudell AeroProbe administration and quantified virus shedding after sheep transduction. In addition, we show that bronchial brushings and biopsies, collected in anaesthetized sheep, can be used to assess SeV-mediated gene expression over time. Similar to mice, gene expression in sheep was transient and had returned to baseline values by day 14. In conclusion, the SeV vector should be strongly considered for lung-related applications requiring a single administration of the vector even though it might not be suitable for diseases requiring repeat administration.

Details

ISSN :
14765462 and 09697128
Volume :
18
Database :
OpenAIRE
Journal :
Gene Therapy
Accession number :
edsair.doi.dedup.....33f786be709b81ad48b82020a7dbeab4
Full Text :
https://doi.org/10.1038/gt.2010.131